Variant NM_000492.4:c.481T>G


Variant details:
Name NM_000492.4:c.481T>G
Protein name NP_000483.3:p.(Tyr161Asp)
Genomic name (hg19) chr7:g.117171160T>G    UCSC    gnomAD
#Exon/intron exon 4
Legacy Name Y161D
Class disease-causing
WT sequence GAGAATAGCTATGTTTAGTTTGATT T ATAAGAAGGTAATACTTCCTTGCAC
Mutant sequence GAGAATAGCTATGTTTAGTTTGATT G ATAAGAAGGTAATACTTCCTTGCAC


External sources:
dbSNP
rs397508729




Response to modulators:


Modulator FDA approval EMA approval in vitro / ex vivo data clinical data
IVAnononono
TEZ-IVAnononono
ELX-TEZ-IVA yesnoyesno


clinical and functional data are provided by Vertex


Pathogenicity predictions:
AGVGD MAPP SIFT PPH2
0 1
no class no class VUS5 VUS5

Color code:   non disease-causing <   VUS1 <   VUS2 <   VUS3 <   VUS4 <   VUS5 <   disease-causing



No patient found in CFTR-NGS catalogue

No patient found in CFTR-France



            CFTR variants are clustered into five groups:
  • CF-causing: when in trans with another CF-causing mutation, will result in CF.
  • CFTR-RD causing: when in trans with a CF-causing mutation, will result in CFTR-related disorders (CFTR-RD) such as chronic pancreatitis, bronchiectasis, CRS-NP (chronic rhinosinusitis with or without nasal polyposis) or CBAVD (congenital absence of vas deferens), according to Bombieri C et al., 2011.
  • Varying clinical consequence: when in trans with another CF-causing mutation, can either result in CF or in a CFTR-RD.
  • Non disease-causing: when in trans with a CF-causing mutation, will not cause CF, nor CFTR-RD.
  • VUS (Variant of unknown clinical significance): unclassified because of insufficient data.